Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2017
(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Charenton-le-Pont, France (December 5, 2017 - 6.00 p.m.) - As of November 30, 2017, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:
| November 30, 2017 | |
| Shares outstanding | 218,805,705 |
| Exercisable voting rights | 234,429,573 |
| Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 235,776,060 |
(*) Shares held by the Company.
About Essilor
Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com.
The Essilor International share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
------------------------
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
